Pietro Ameri, Valentina Mercurio, Piero Pollesello, Markus S Anker, Johannes Backs, Antoni Bayes-Genis, Barry A Borlaug, Daniel Burkhoff, Sergio Caravita, Stephen Y Chan, Frances de Man, George Giannakoulas, Aránzazu González, Marco Guazzi, Paul M Hassoun, Anna R Hemnes, Cristoph Maack, Brendan Madden, Vojtech Melenovsky, Oliver J Müller, Zoltan Papp, Soni Savai Pullamsetti, Peter P Rainer, Margaret M Redfield, Stuart Rich, Gabriele G Schiattarella, Hall Skaara, Kostantinos Stellos, Ryan J Tedford, Thomas Thum, Jean Luc Vachiery, Peter van der Meer, Sophie Van Linthout, Piotr Pruszczyk, Petar Seferovic, Andrew J S Coats, Marco Metra, Giuseppe Rosano, Stephan Rosenkranz, Carlo Gabriele Tocchetti
Pulmonary hypertension (PH) associated with left heart failure (LHF) (PH-LHF) is one of the most common causes of PH. It directly contributes to symptoms and reduced functional capacity and negatively affects right heart function, ultimately leading to a poor prognosis. There are no specific treatments for PH-LHF, despite the high number of drugs tested so far. This scientific document addresses the main knowledge gaps in PH-LHF with emphasis on pathophysiology and clinical trials. Key identified issues include better understanding of the role of pulmonary venous versus arteriolar remodelling, multidimensional phenotyping to recognize patient subgroups positioned to respond to different therapies, and conduct of rigorous pre-clinical studies combining small and large animal models...
April 19, 2024: European Journal of Heart Failure